	US 12,453,774 B2
	Tumor immunotherapy polypeptide and application thereof
Si Qiu, Hubei (CN); Bo Li, Hubei (CN); Youping Li, Hubei (CN); and Le Zhang, Hubei (CN)
Assigned to GENOIMMUNE THERAPEUTICS CO., LTD., Wuhan (CN)
Appl. No. 17/774,872
Filed by GENOIMMUNE THERAPEUTICS CO., LTD., Hubei (CN)
PCT Filed Nov. 7, 2019, PCT No. PCT/CN2019/116166 § 371(c)(1), (2) Date May 6, 2022, PCT Pub. No. WO2021/087840, PCT Pub. Date May 14, 2021.
Prior Publication US 2022/0378887 A1, Dec. 1, 2022
Int. Cl. A61K 40/42 (2025.01); A61K 40/11 (2025.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61P 35/00 (2006.01)

CPC A61K 40/42 (2025.01) [A61K 40/11 (2025.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61P 35/00 (2018.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/55 (2023.05)]

15 Claims

1. A construct, comprising:

a nucleic acid encoding a group of separate polypeptides, wherein the group of separate polypeptides comprises at least three polypeptides selected from the group consisting of amino acid sequences set forth in SEQ ID NO: 1 to SEQ ID NO: 6, wherein the at least three polypeptides have separate amino acid sequences; and

a control sequence,

wherein the control sequence is operably linked to the nucleic acid.